Keywords: sinobiopharma, building, momentum, poised, move, higher, says
Sinobiopharma building momentum and poised for a move higher, says Beacon
Article | 18 May 2009
China's Sinobiopharma (SNBP) could benefit greatly from the tremendous growth in the Chinese pharmaceutical market - 30% annually between 2000 and 2005, say ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
